A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
Status:
Completed
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
This international, multi-center, Phase 2/3 trial will study the safety, tolerability, and
efficacy of bardoxolone methyl in qualified patients with Alport syndrome. The Phase 2
portion of the trial will be open-label and enroll up to 30 patients. The Phase 3 portion of
the trial will be double-blind, randomized, placebo-controlled and will enroll up to 180
patients.